| Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data (NCT05438888) | Pfizer | 2022-07-01 |
| Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation (NCT05320627) | China National Center for Cardiovascular Diseases | 2022-03-30 |
| A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated With a NOAC for This Indication With a Special Focus on Their Fear of Bleeding While Using a NOAC vs the Clinical Benefit of a NOAC of Thrombosis/Stroke Prevention. (NCT04722679) | Bayer | 2021-05-11 |
| Study of the Effects of Anticoagulant Interruption Covered by Percutaneous Left Atrial Occlusion in Patients With Chronic Atrial Fibrillation and Radiation Cystitis at Risk of Bleeding (NCT04701749) | University Hospital, Clermont-Ferrand | 2021-02-24 |
| Evaluation of Safety and Performance of the Omega™ LAA (Left Atrial Appendage) Occluder and Omega™ Delivery System in Patients With Non-Valvular Atrial Fibrillation and High Bleeding Risk (NCT04829929) | Eclipse Medical Ltd. | 2020-11-17 |
| Left Atrial Appendage Closure as Secondary Prevention of Atrial Fibrillation-related Embolic Events (NCT04559243) | Lifetech Scientific (Shenzhen) Co., Ltd. | 2020-11-12 |
| Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (NCT04519944) | Daiichi Sankyo | 2020-06-30 |
| Observe the Safety and Effectiveness of the WATCHMAN FLX™ for Subjects in Hong Kong (NCT04096963) | Boston Scientific Corporation | 2020-06-19 |
| Study to Gather Information on the Kidney Function of Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) Treated With Rivaroxaban or Vitamin K Antagonists (NCT04297072) | Bayer | 2020-05-01 |
| The Conformal Prague Study (NCT04193826) | Conformal Medical, Inc | 2019-10-19 |
| Watchman FLX Left Atrial Appendage Closure Device Post Approval Study ( Europe Only) (NCT02654470) | Boston Scientific Corporation | 2019-07-16 |
| Registry to Evaluate Chinese Real-World Clinical Outcomes in Patients With AF Using the WATCHMAN Left Atrial Appendage Closure Technology (NCT03917563) | Xijing Hospital | 2019-04-20 |
| LAMax Vs. Watchman LAAC Device for Subjects With Non-valvular AF to Reduce the Risk of Stroke (NCT04429646) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2019-04-20 |
| A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients. (NCT03715725) | Bayer | 2018-10-31 |
| Safety and Effectiveness of Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation (NCT03570047) | Pfizer | 2018-05-08 |
| Rivaroxaban in Patients With Atrial Fibrillation Undergoing PCI (NCT03315650) | IHF GmbH - Institut für Herzinfarktforschung | 2018-01-01 |
| Study to Describe Risk of Bleeding in Patients Depending on the Different Anticoagulant Therapy They Are on for Atrial Fibrillation (AF) (NCT03508258) | Bristol-Myers Squibb | 2017-09-01 |
| Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm (NCT03515083) | Saint Luke's Health System | 2017-07-17 |
| A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure (NCT03088072) | Scripps Health | 2017-03-23 |
| Canadian Left Atrial Appendage Closure Study (NCT03133806) | Cardia Inc. | 2017-02-15 |
| Study of Safety and Efficacy of a Left Atrial Appendage Occulder (NCT02937025) | Ya-Wei Xu | 2017-01-01 |
| Evolution of Coagulation Activity in Non Valvular Atrial Fibrillation Patients Under Apixaban (NCT03136510) | Hopital Lariboisière | 2016-09-01 |
| Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation (NCT03087487) | Bristol-Myers Squibb | 2016-06-01 |
| Bleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial Fibrillation (NCT03002740) | Bristol-Myers Squibb | 2016-01-31 |
| Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center (NCT02502396) | M.D. Anderson Cancer Center | 2015-09-28 |
| Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized With PCI - The AVIATOR 2 Registry (NCT02362659) | Icahn School of Medicine at Mount Sinai | 2015-04-01 |
| Therapy With New Oral Anticoagulants (NCT02222090) | Sheba Medical Center | 2014-07-01 |
| Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany, UK and France: REACT-AF2 (NCT02488421) | Bristol-Myers Squibb | 2014-06-01 |
| Better Adherence With New Oral Anticoagulant in Atrial Fibrillation : Effectiveness of a Personalized Education Program (NCT02422602) | University Hospital, Montpellier | 2013-11-26 |
| Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN) (NCT01884350) | Bristol-Myers Squibb | 2013-10-15 |
| Local Adaptation of Cost Effectiveness Model for Apixaban Atrial Fibrillation Indication - Venezuela (NCT02756481) | Bristol-Myers Squibb | 2013-10-01 |
| Evaluation of Effectiveness and Safety of Xa Inhibitor for the Prevention of Stroke And Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-valvular Atrial Fibrillation (NCT02147444) | Tohoku University | 2012-11-01 |
| Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment (NCT01857622) | Daiichi Sankyo Co., Ltd. | 2011-11-01 |